All In Biotech

Drug Trial Radar · NCT05026008

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SR1375

A Randomized, Double-blind, Placebo-controlled, 2-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of SR1375 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Nov 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Sep 30, 2021

Primary completion

Nov 30, 2022

Study completion Mar 30, 2023

Sponsor

Sponsor type
Industry
First posted
Aug 30, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, 2-part study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of SR1375 in healthy volunteers

Conditions

  • Healthy Volunteers

Interventions

  • SR1375Drug

    The subject will be orally administered by single and multiple doses of SR1375 capsules with 240 ml water

  • Matching placeboDrug

    The subject will be orally administered by single and multiple doses of matching capsules with 240 ml water

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AE (Adverse Event)Time frame: Up to Day 32

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Linear Clinical Research Ltd

    Nedlands, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.